Harmony Biosciences Holdings, Inc. (HRMY)
39.64
+0.37
(+0.94%)
USD |
NASDAQ |
Dec 11, 15:06
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 2.283B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 20.06% |
| Valuation | |
| PE Ratio | 12.48 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 2.806 |
| Price to Book Value | 2.734 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.2719 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 68.48% |
Profile
| Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the provision of development and commercialization of therapies for the treatment of neurological disorders. Its product, WAKIX, is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded by Jeffrey S. Aronin on July 25, 2017 and is headquartered in Plymouth Meeting, PA. |
| URL | http://www.harmonybiosciences.com |
| Investor Relations URL | https://ir.harmonybiosciences.com/ |
| HQ State/Province | Pennsylvania |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Feb. 24, 2026 (est.) |
| Last Earnings Release | Nov. 04, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the provision of development and commercialization of therapies for the treatment of neurological disorders. Its product, WAKIX, is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded by Jeffrey S. Aronin on July 25, 2017 and is headquartered in Plymouth Meeting, PA. |
| URL | http://www.harmonybiosciences.com |
| Investor Relations URL | https://ir.harmonybiosciences.com/ |
| HQ State/Province | Pennsylvania |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Feb. 24, 2026 (est.) |
| Last Earnings Release | Nov. 04, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |